Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 14Recruiting 10Unknown 7Terminated 5Not yet recruiting 4

Sponsor Class

OTHER_GOV 2OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 133Breast Neoplasms 95Colorectal Neoplasms 65Carcinoma, Hepatocellular 57Squamous Cell Carcinoma of Head and Neck 48Stomach Neoplasms 46Lung Neoplasms 44Triple Negative Breast Neoplasms 43Prostatic Neoplasms 43Leukemia, Myeloid, Acute 43Small Cell Lung Carcinoma 41Uterine Cervical Neoplasms 40Rectal Neoplasms 37Neoplasms 31Pancreatic Neoplasms 30Recurrence 29Neoplasm Metastasis 29Esophageal Squamous Cell Carcinoma 25Esophageal Neoplasms 24Ovarian Neoplasms 23Nasopharyngeal Carcinoma 21Carcinoma, Renal Cell 21Brain Neoplasms 21Melanoma 20Lymphoma, Large B-Cell, Diffuse 20Colonic Neoplasms 20Endometrial Neoplasms 19Multiple Myeloma 18Head and Neck Neoplasms 18Biliary Tract Neoplasms 18

Interventions

Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Meningeal Carcinomatosis × Clear all
NCT07551414 2026-04-24

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
38 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06971406 2025-05-14

FLAME-1

Henan Cancer Hospital

Phase 2 Not yet recruiting
100 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06861218 2025-03-06

Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
42 enrolled
CNS

Meningeal Carcinomatosis

NCT06441045 2024-06-04

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Fujian Cancer Hospital

Phase 2 Not yet recruiting
112 enrolled
CNS

Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡